Plasmalogens for Health & Longevity
Evidence Review created on 11/08/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Plasmalogen, Plasmenyl Phospholipids, Alkenyl Phospholipids, Vinyl-Ether Phospholipids, Ethanolamine Plasmalogen, PlsEtn, PE(P), Choline Plasmalogen, PlsCho, PC(P)
Motivation
Plasmalogens are a family of fats that form part of the outer layer of every cell. A special chemical link in their structure reacts readily with damaging forms of oxygen, and they are especially plentiful in the brain, heart, and immune cells. The body makes them itself, but supplements extracted from scallops, sea squirts, or chicken, and oils that the body turns into plasmalogens, are now sold to people interested in brain health and healthy aging.
Interest grew from research comparing plasmalogen levels in blood and brain tissue across age groups and between people with and without Alzheimer’s disease, along with experiments in aging mice. Research groups in Japan then began testing small daily amounts of purified marine extracts against placebo capsules, while a Canadian company developed high-dose oils designed to raise levels more strongly.
This review examines the human evidence on plasmalogen supplements and the oils the body converts into them, covering memory, mood, and metabolic health, their safety, dosing, product quality, and the open questions that matter to adults pursuing a longer, healthier life.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
The items below give a high-level overview of plasmalogen biology, the supplementation hypothesis, and the debate around it.
-
Plasmalogens Alleviate Age-Related Cognitive Decline in Mice - Arkadi Mazin
Readable account of a 2022 aged-mouse study showing synaptic and anti-inflammatory effects; its summary of the earlier human trial overstates that trial’s results, which is worth noting when reading it.
-
Episode #186: Plasmalogens with Dr. Dayan Goodenowe, PhD - Scott Forsgren
Long-form interview presenting the plasmalogen-deficiency hypothesis of aging and dementia by the founder of Prodrome Sciences, which sells precursor oils and blood tests; the host is an affiliate of that company.
-
Plasmalogens and Alzheimer’s disease: a review - Su et al., 2019
Narrative review of plasmalogen loss in Alzheimer’s disease, proposed protective mechanisms, and the early human supplementation trials, written by academic lipid researchers.
-
Plasmalogens: A potential therapeutic target for neurodegenerative and cardiometabolic disease - Paul et al., 2019
Review from Peter Meikle’s Melbourne group covering strategies to raise plasmalogens, including alkylglycerol precursors and inositol, with a cardiometabolic focus that most brain-centered sources lack.
-
Plasmalogen Replacement Therapy - Bozelli & Epand, 2021
Overview of the different replacement strategies, from natural extracts to synthetic precursors, and the disease settings in which each has been tested.
FoundMyFitness (Rhonda Patrick) mentions plasmalogens only briefly, in a Science Digest summary of a ketogenic-diet study, which gives no overview of plasmalogens. No relevant content was found from Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension Magazine in web and on-site searches; Lifespan.io is the only priority source with a dedicated article.
Grokipedia
AI-written encyclopedia entry on plasmalogen structure, peroxisomal synthesis, tissue distribution, and RCDP (rhizomelic chondrodysplasia punctata, an inherited disorder of plasmalogen synthesis); useful for biochemical background rather than supplementation evidence.
Examine
Examine treats plasmalogens as a measured outcome rather than a supplement; its database grades one small trial (17 participants) in which inositol slightly increased plasmalogen levels.
ConsumerLab
Do plasmalogen supplements improve cognitive function and memory?
Reviews the human trials, their industry funding, safety, a seafood-allergy caution, and product costs; concludes that evidence for supplementation is very limited.
Systematic Reviews
No systematic reviews or meta-analyses for Plasmalogens were found on PubMed as of November 7, 2026.
Neither the claimed cognitive benefit nor any safety outcome is represented by a systematic review or meta-analysis.
Mechanism of Action
Plasmalogens are membrane phospholipids with a vinyl-ether bond at the first carbon and a polyunsaturated fatty acid such as DHA (docosahexaenoic acid, an omega-3 fat) at the second, and make up to 20% of human phospholipid mass (Braverman 2012). In peroxisomes (small fat-processing organelles), GNPAT (glyceronephosphate O-acyltransferase, which starts the pathway) and AGPS (alkylglycerone phosphate synthase, which forms the ether bond) start synthesis (Braverman 2012); inherited defects cause RCDP (Braverman 2012).
- Antioxidant shield: the vinyl-ether bond reacts with reactive oxygen species, protecting cultured cells (Zoeller 1999).
- Signaling: in neurons, plasmalogens activate orphan GPCRs (G-protein-coupled receptors, cell-surface signal receivers) linked to neuronal survival (Hossain 2016).
- Brain inflammation: oral plasmalogens reduced microglial (brain immune cell) activation in old mice (Gu 2022).
- Competing view: the mechanisms are poorly defined (Paul 2019); 2 mg/day marine extract did not raise plasma plasmalogens in a trial funded by the manufacturer-backed Japanese Plasmalogen Society (Fujino 2022); polyunsaturated ether lipids also feed ferroptosis (iron-dependent cell death) (Zou 2020).
- Pharmacology: structural lipids without receptor selectivity. In mice, oral plasmalogens are absorbed after hydrolysis at the second carbon (Yamashita 2021) and peak in plasma at 4–8 hours (Yamashita 2021). In a trial run by developer Med-Life Discoveries, the precursor PPI-1011 was converted to PlsEtn 16:0/22:6 (an ethanolamine plasmalogen carrying DHA), peaking at 48–53 hours (Smith 2025) with a 63–86-hour half-life (Smith 2025). Breakdown uses plasmalogen-selective phospholipase A2 (Farooqui 2010), not liver drug enzymes; tissue distribution of supplements in humans is unmeasured.
Historical Context & Evolution
Plasmalogens were first described in the 1920s as membrane lipids that release aldehydes in a tissue-staining reaction, and they had no original therapeutic use. Medical relevance came from peroxisomal disorders such as RCDP and Zellweger syndrome (inherited absence of peroxisomes), in which missing plasmalogen synthesis causes severe developmental disease (Braverman 2012).
Interest in aging followed post-mortem studies showing reduced ethanolamine plasmalogens in Alzheimer’s disease brain regions (Ginsberg 1995), including early-stage disease (Han 2001). Dayan Goodenowe and colleagues at Phenomenome Discoveries, a diagnostics company, reported lower serum levels that tracked dementia severity (Goodenowe 2007); Goodenowe later founded Prodrome Sciences, which sells precursor oils and plasmalogen blood tests.
In Fukuoka, Takehiko Fujino’s group purified scallop plasmalogens and ran the largest randomized trial, in mild cognitive impairment and mild Alzheimer’s disease, funded by the Japanese Plasmalogen Society, whose donors include the extract supplier B&S Corporation; authors Fujino and Mawatari hold patent applications on the extraction method (Fujino 2017). Manufacturers then ran trials in healthy adults: Sunsho and Nihon Pharmaceutical with a sea squirt extract (Watanabe 2020) and B&S Corporation with its scallop extract (Fukuchi 2026). In Melbourne, Peter Meikle’s publicly funded group linked blood plasmalogen patterns to cardiometabolic health and mortality (Beyene 2024).
Opinion has moved in both directions. The 2017 trial missed its primary endpoint (Fujino 2017), and the only peer-reviewed report of gram-dose precursor oils in cognitively impaired people was retracted in 2026 (Frontiers retraction notice); meanwhile, the 2026 trial in healthy adults met its primary memory endpoint (Fukuchi 2026).
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: memory gains from randomized trials by two independent industry groups are outweighed by a larger null randomized trial (Fujino 2017), and no other clinical outcome has been replicated in placebo-controlled trials.
Medium 🟩 🟩
No benefit reaches Medium: the only single-trial mood signal comes from secondary scales of a randomized trial whose primary endpoint was null, and the other human data are uncontrolled, indirect, or outweighed by a larger null trial.
Low 🟩
Mood and Mental Fatigue ⚠️ Conflicted
In an RCT (randomized controlled trial) of 40 male athletes, 2 mg/day scallop plasmalogen lowered POMS 2 (Profile of Mood States, a mood scale) anger-hostility and fatigue-inertia versus placebo (Fujino 2022). The primary endpoint was null (Fujino 2022); vigor fell (Fujino 2022). Net: the null primary endpoint outweighs subscale gains.
Magnitude: At 4 weeks, fatigue-inertia T-score (standardized score, population mean 50) 5.5 points lower than placebo (95% CI (confidence interval, the range of plausible true values) −9.2 to −1.8) (Fujino 2022) and anger-hostility 4.3 points lower (−7.0 to −1.6) (Fujino 2022); total mood disturbance 2.5 points lower (−5.2 to 0.2, not significant) (Fujino 2022).
Memory and Cognitive Performance ⚠️ Conflicted
Two industry-run RCTs in forgetful, healthy adults found memory gains with 1 mg/day (Watanabe 2020; Fukuchi 2026). The largest RCT, in MCI (mild cognitive impairment) or mild Alzheimer’s disease, missed its primary endpoint (Fujino 2017), possibly because populations and tests differed. Net: the larger null trial weighs more.
Magnitude: Verbal memory standardized score 10.1 points higher than placebo after 12 weeks (95% CI 0.4 to 19.9) (Fukuchi 2026); in MCI or mild Alzheimer’s disease, the 30-point MMSE-J (Japanese Mini-Mental State Examination, a cognitive screen) rose 0.40 points with plasmalogen versus 0.32 with placebo at 24 weeks, a non-significant difference (Fujino 2017).
Quality of Life in Parkinson’s Disease
In an open-label (participants knew their treatment) series of 10 people with Parkinson’s disease, 1 mg/day scallop-derived ether phospholipids for 24 weeks raised blood plasmalogens (Mawatari 2020) and improved quality-of-life scores, but not mobility (Mawatari 2020). There was no placebo group; authors are the patent-holding Fukuoka group.
Magnitude: PDQ-39 (Parkinson’s Disease Questionnaire, a quality-of-life scale; lower is better) total score fell from 273.5 to 188.8 over 24 weeks (no control group) (Mawatari 2020), while the mobility subscale moved from 50.5 to 48.8 (no control group) (Mawatari 2020).
Blood Lipids and Inflammation Markers
In a 10-man crossover RCT (treatments in turn), 4 g/day shark liver oil raised plasmalogens (Paul 2021) and lowered cholesterol and triglycerides versus placebo (Paul 2021). Indirect: alkylglycerol precursors. A CRP (C-reactive protein, inflammation marker) fall, significant in the abstract, lost significance after full-text adjustment for many outcomes (Paul 2021).
Magnitude: Triglycerides 2.25 to 1.64 mmol/L with shark liver oil versus 2.01 to 2.18 mmol/L with placebo, significant versus placebo (Paul 2021); total cholesterol 5.36 to 4.98 versus 5.35 to 5.49 mmol/L, significant versus placebo (Paul 2021).
Lower Cardiometabolic Risk and Mortality
In 10,339 Australian adults, a higher plasmalogen score (an index of blood levels) was linked to less type 2 diabetes (Beyene 2024), less cardiovascular disease (Beyene 2024), and lower 17-year mortality (Beyene 2024). Evidence is indirect: it concerns the body’s own levels, not supplements, and other factors may explain it.
Magnitude: Top versus bottom fifth of the score: HR (hazard ratio, the relative rate of death over time) 0.66 (95% CI 0.56 to 0.78) for all-cause mortality (Beyene 2024) and OR (odds ratio, the relative odds) 0.39 (0.25 to 0.61) for incident type 2 diabetes (Beyene 2024).
Speculative 🟨
Neuroprotection and Reduced Brain Inflammation
In aged female mice, two months of oral plasmalogens improved learning (Gu 2022), reduced hippocampal synapse loss (Gu 2022), and reduced microglial activation (Gu 2022). Basis is animal and cell data only.
Antioxidant Protection of Cell Membranes
In cultured cells lacking plasmalogens, restoring the vinyl-ether bond protected against oxidative damage (Zoeller 1999). No human study links supplementation to oxidative outcomes; the basis is mechanistic only.
Benefit-Modifying Factors
- Genetic polymorphisms: In a cross-sectional study by Prodrome Sciences, carriers of APOE4 (a variant of the apolipoprotein E gene, which encodes a cholesterol-transport protein) with high serum plasmalogens had dementia prevalence similar to non-carriers (Goodenowe 2019). No trial has tested genotype-specific response.
- Baseline biomarker levels: In Alzheimer’s disease, serum plasmalogens at or below 75% of control levels predicted faster cognitive decline in a pilot by Phenomenome-affiliated authors (Wood 2010). Mood benefit was larger with higher baseline mood disturbance (Fujino 2022).
- Sex: In mild Alzheimer’s disease, delayed memory improved versus placebo only in women (Fujino 2017). Men have higher plasmalogen scores than women (Beyene 2024), and some ether phospholipid classes decline with age only in men (Beyene 2020).
- Pre-existing conditions: A near-significant memory signal in the largest trial appeared in mild Alzheimer’s disease, not in MCI (Fujino 2017). Lipid effects of shark liver oil were shown in overweight or obese men (Paul 2021).
- Age: In mild Alzheimer’s disease, benefit appeared below age 77 (Fujino 2017), whereas in a trial co-authored by extract maker Sunsho Pharmaceutical, a sea squirt plasmalogen-plus-elastin combination improved some memory scores in people aged 75 or older (Yamada 2024).
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no adverse event has been shown in excess of placebo in trials from more than one independent research group.
Medium 🟥 🟥
No risk reaches Medium: placebo-controlled trials of marine extracts show no excess adverse events, and the harms observed come from a synthetic precursor or from whole-organism allergen exposure.
Low 🟥
Gastrointestinal Effects ⚠️ Conflicted
Oily precursors often cause mild digestive complaints, but in a placebo-controlled phase 1 PPI-1011 trial these were the most common events in both groups (Smith 2025). In the 24-week scallop-extract trial, diarrhea and constipation were rare in both arms (Fujino 2017). Net: no excess risk is shown.
Magnitude: Single-dose phase: 43.3% of PPI-1011 versus 40% of placebo recipients reported any adverse event (Smith 2025), half of all events gastrointestinal (Smith 2025); scallop extract: diarrhea in 3 of 169 versus 1 of 167 placebo recipients (Fujino 2017), constipation in 2 versus 0 (Fujino 2017).
Liver Injury with Precursors
One participant taking 75 mg/kg/day PPI-1011 stopped on day 8 for mild ALT and AST (liver enzymes) rises judged probably treatment-related (Smith 2025). A case report describes acute toxic hepatitis after two weeks of shark liver oil capsules, resolving on withdrawal (Kilincalp 2012). Evidence is indirect: precursors, not marketed extracts.
Magnitude: Liver-test adverse events in 2 of 12 PPI-1011 recipients (1 discontinued for a grade 1 rise) versus 0 of 4 placebo recipients in the multiple-dose phase (Smith 2025); one shark liver oil hepatitis case (no control group) (Kilincalp 2012).
Allergic Reactions in Seafood-Sensitive People
Marketed extracts come from scallops or sea squirts. A review of occupational asthma in Japan describes sea squirt antigens causing asthma in seafood workers (Dobashi 2012), and the largest trial excluded scallop-allergic people (Fujino 2017). Evidence is indirect: whole-organism exposure, not purified lipid extracts.
Magnitude: Not quantified in available studies. No trial has given purified extracts to seafood-allergic people, so no reaction rate exists.
Speculative 🟨
Ferroptosis Sensitization
Polyunsaturated ether phospholipids made by peroxisomes supply the substrate for ferroptosis in cancer cells, neurons, and heart muscle cells (Zou 2020). Basis is cell and mouse data only.
Support of Tumor Lipid Metabolism
AGPS is up-regulated in aggressive human cancer cells, and removing it reduced tumor growth in mice (Benjamin 2013). Whether supplied plasmalogens aid existing tumors is untested; basis is mechanistic only.
Risk-Modifying Factors
- Genetic polymorphisms: No pharmacogenetic data exist. Inherited peroxisomal defects, including mutations in PEX7 (the gene for a receptor that imports AGPS into peroxisomes), GNPAT, or AGPS, cause RCDP, where replacement is being developed as a medical treatment (NCT04031287).
- Baseline biomarker levels: Pre-existing ALT or AST elevation makes a precursor-related rise harder to detect; the developer calls for liver-enzyme monitoring in future precursor studies (Smith 2025).
- Sex: No sex difference in adverse events has been reported; the phase 1 precursor trial enrolled 50% women (Smith 2025) and withdrew one participant who became pregnant (Smith 2025).
- Pre-existing conditions: Seafood allergy is an inferred concern with marine extracts, based on sea squirt antigen asthma in exposed workers (Dobashi 2012); active cancer is a theoretical concern from ether-lipid tumor signaling (Benjamin 2013).
- Age: Adults aged 60 to 85 took 1 mg/day for 24 weeks without notable differences in adverse events versus placebo (Fujino 2017); older adults more often take anticoagulants (drugs that slow blood clotting), relevant to DHA-rich precursor oils.
Key Interactions & Contraindications
Documented interactions:
- Statins (cholesterol-lowering drugs; rosuvastatin studied; atorvastatin and simvastatin untested): In a crossover RCT, rosuvastatin 10–40 mg/day lowered plasma ethanolamine plasmalogens by about 23–24% versus placebo (Ng 2014). Consequence: lower measured levels that can mask supplement effects; testing on a stable statin dose avoids misreading.
- Krill oil: 30 days of krill oil enriched omega-3 ether phospholipids in plasma more than fish oil (Sung 2022). Consequence: additive rise in circulating ether lipids; combined intake is counted when interpreting blood levels.
- Shark liver oil (alkylglycerols): 4 g/day raised plasma plasmalogens (Paul 2021) and lowered triglycerides versus placebo (Paul 2021). Consequence: additive plasmalogen raising and lipid lowering; lipid panels taken before and after starting show the combined effect.
- Myo-inositol: 2 weeks of myo-inositol raised serum plasmalogens in 17 adults with high blood lipids (Maeba 2008), and chronic dosing raised brain ethanolamine plasmalogens by 10% in rats (Pettegrew 2001). Consequence: additive rise in measured plasmalogens; both are counted when interpreting plasmalogen tests.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Anticoagulants and antiplatelet drugs (drugs that curb blood clotting; warfarin, apixaban, clopidogrel, aspirin): DHA-rich precursor oils supply omega-3 fatty acids with mild antiplatelet activity, inferred to add bleeding tendency. Mitigation: more frequent INR (international normalized ratio, a clotting test) checks when starting with warfarin.
- Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs; ibuprofen, naproxen): additive platelet inhibition inferred with DHA-rich precursor oils, raising bruising or bleeding risk. Mitigation: limiting regular combined use and watching for bruising.
- Orlistat (Alli, Xenical): blocks fat-digesting lipases; absorption of ingested plasmalogens depends on hydrolysis at the second carbon (Yamashita 2021), so reduced uptake is inferred. Mitigation: taking plasmalogens with a meal not paired with orlistat.
Populations who should avoid Plasmalogens:
- People with scallop, mollusk, or sea squirt allergy (marine-derived extracts): Avoid. Inferred from sea squirt antigen allergy in exposed workers, described in a review (Dobashi 2012); no data on purified extracts.
- People with active cancer: inferred from AGPS-driven ether-lipid support of tumor growth in mice (Benjamin 2013); no human data.
- People with liver disease (high-dose precursor oils): inferred from a probably treatment-related ALT rise in a healthy volunteer (Smith 2025); no data in liver disease.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Seafood-free source for allergic users: chicken-derived extracts or synthetic precursors avoid scallop and sea squirt proteins, preventing allergic reactions in people with seafood allergy.
- Taking oil-based products with meals: reduces gastrointestinal discomfort from oily precursors; the phase 1 precursor trial dosed participants in the fed state (Smith 2025).
- Liver enzyme checks on high-dose precursors: ALT and AST at baseline and after 4–8 weeks; dosing was stopped at a grade 1 (mild) elevation in the phase 1 trial (Smith 2025), limiting liver injury risk.
- Bleeding checks with anticoagulants: INR within 1–2 weeks of starting a DHA-rich precursor with warfarin, and attention to bruising, limits the inferred bleeding risk.
- Starting at trial doses: 0.5 mg/day (Yamada 2024) to 1 mg/day (Fujino 2017) of purified extract keeps exposure within studied ranges and lowers the chance of unstudied adverse effects.
- Deferring use during active cancer: avoids the theoretical support of tumor lipid metabolism and ferroptosis-related effects until data exist.
Therapeutic Protocol
Timing, titration steps, and cycling below reflect common practice unless cited.
- Standard marine extract dose: 1 mg/day purified scallop plasmalogen, split as 0.5 mg twice daily, for 24 weeks (Fujino 2017), popularized by Takehiko Fujino and the manufacturer-funded Japanese Plasmalogen Society.
- Alternative marine doses: 1 mg/day once daily for 12 weeks (Fukuchi 2026); 1 mg/day sea squirt extract (Watanabe 2020); 2 mg/day for 4 weeks (Fujino 2022).
- Low-dose product: 0.5 mg/day of a scallop-oil product (Daiwa Brain Health) for 90 days in an open-label comparison without placebo, run by a Daiwa Health Development advisory board member (Pescatore 2024).
- Precursor approach: DHA-precursor oils (ProdromeNeuro, ProdromeGlia), labeled 900 mg per 2-capsule serving (ConsumerLab plasmalogen article), are promoted by Prodrome Sciences founder Dayan Goodenowe; their dosing report was retracted (Frontiers retraction notice). Shark liver oil alkylglycerols: 4 g/day (Paul 2021).
- Investigational precursor: PPI-1011 at 75–100 mg/kg/day was tested only in a 14-day phase 1 trial (Smith 2025) and is not available outside trials.
- Time of day: no trial compared timings; recent Japanese trials gave capsules in the morning (NCT06907537; NCT06715475), and oily products are usually taken with a fat-containing meal.
- Half-life: after the precursor PPI-1011, the resulting plasmalogen has a half-life of 63–86 hours (Smith 2025); the human half-life of marine extracts has not been measured.
- Single versus split dose: the largest trial split the dose twice daily (Fujino 2017), while others used once-daily dosing (Watanabe 2020; Yamada 2024); no trial compared the two.
- Genetic polymorphisms: Prodrome Sciences proposes that APOE4 carriers need higher plasmalogen status, based on observational data (Goodenowe 2019); no genotype-guided dosing has been tested.
- Sex: memory signals in women only (Fujino 2017) have not led to sex-specific dosing; the same doses are used for men and women.
- Age: subgroup signals point in different directions for those under 77 (Fujino 2017) and those 75 or older (Yamada 2024); no age-specific dose exists.
- Baseline biomarker levels: the positive 2026 trial enrolled only adults with below-average verbal memory (Fukuchi 2026); low blood plasmalogens are not yet used to set dose.
- Pre-existing conditions: Parkinson’s disease was studied at 1 mg/day (Mawatari 2020); obesity with shark liver oil (Paul 2021); in seafood allergy, non-marine sources avoid scallop and sea squirt proteins.
Discontinuation & Cycling
- Short-term versus lifelong: trials lasted from 4 weeks (Fujino 2022) to 24 weeks (Fujino 2017); whether benefits need continuous lifelong use is unknown, and no trial exceeds six months.
- Withdrawal effects: none reported; after stopping at 24 weeks, blood ether phospholipids tended to fall back in Parkinson’s patients (Mawatari 2020).
- Tapering: no tapering protocol has been studied or appears necessary, as no withdrawal syndrome is described.
- Cycling: no evidence shows that cycling maintains efficacy; all trials used continuous daily dosing.
Sourcing and Quality
- Source organism: extracts come from scallops (Mizuhopecten yessoensis), sea squirts (Halocynthia roretzi), or chicken breast; precursors come from shark liver oil or synthetic and algae-based alkylglycerols. Sea squirt viscera and blue mussels are among the richest food sources (Yamashita 2016).
- Labeled content: labels may state milligrams of plasmalogen or of total extract; trial doses refer to 0.5–2 mg of plasmalogen itself, so products stating only extract weight are hard to compare.
- Third-party testing: no independent seal programs for plasmalogens are known; a certificate of analysis showing plasmalogen content and heavy-metal testing for marine sources is the practical quality marker.
- Brands: Daiwa Brain Health and NeuroREGAIN (purified marine extracts) and ProdromeNeuro and ProdromeGlia (Prodrome Sciences precursors) are the products ConsumerLab reviewed (ConsumerLab plasmalogen article); B&S Corporation supplied the Japanese trial extract.
- Stability: the vinyl-ether bond is sensitive to oxidation (Zoeller 1999), so cool storage and attention to expiry dates help preserve content.
Practical Considerations
- Time to effect: memory differences appeared at 8–12 weeks (Watanabe 2020) and mood changes at 4 weeks (Fujino 2022).
- Common pitfalls: treating precursor oils and purified extracts as interchangeable; citing the retracted precursor trial; and expecting 2 mg/day to reliably raise plasma levels, which did not happen in athletes (Fujino 2022).
- Regulatory status: in the US, plasmalogens are sold as dietary supplements, and the FDA (US Food and Drug Administration) does not have the authority to approve supplements before marketing (FDA Q&A on Dietary Supplements); PPI-1011 remains investigational (NCT05969977).
- Cost and access: products cost about $2.55 to $6.63 per daily serving (ConsumerLab plasmalogen article) and are sold mainly online.
Interaction with Foundational Habits
- Sleep: possible potentiating effect. Insomnia scores fell 1.2 points more than placebo at 2 weeks in athletes (95% CI −2.5 to 0.1, not significant) (Fujino 2022); a dedicated sleep trial has finished without posted results (NCT06907537). No sleep disruption has been reported.
- Nutrition: direct. Mussels, sea squirts, scallops, and chicken supply plasmalogens (Yamashita 2016). In Australian adults, red meat, poultry, eggs, and fish intake were linked to higher plasmalogen scores (Beyene 2024) and alcohol to markedly lower ones (Beyene 2024). Oily products are taken with meals.
- Exercise: none shown. Four weeks of 2 mg/day did not change grip strength, jump distance, or VO2max (maximal oxygen uptake) in athletes (Fujino 2022); exercise time was only marginally linked to plasmalogen scores (Beyene 2024).
- Stress management: indirect. Fatigue and anger-hostility scores fell versus placebo in athletes (Fujino 2022), but cortisol was not measured; smoking was linked to lower plasmalogen scores (Beyene 2024).
Monitoring Protocol & Defining Success
Baseline testing before starting covers liver enzymes for anyone planning high-dose precursor oils, a fasting lipid panel for alkylglycerol or shark liver oil users, and a repeatable cognitive test so that later change can be judged against a personal starting point. A blood plasmalogen measurement is optional, because no clinical target exists and a statin can lower readings (Ng 2014). Ongoing monitoring repeats liver enzymes at 4–8 weeks and then every 6 months on precursor oils, the lipid panel at 8–12 weeks, and cognitive testing at 12 weeks and then every 6–12 months, matching the 12-week (Fukuchi 2026) to 24-week (Mawatari 2020) windows in which trials detected change. Success is a consistent improvement on the same test, confirmed on repeat, without adverse effects.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Blood ethanolamine plasmalogen (plasma or red-cell PlsEtn) | No established target; track change from own baseline | Marker expected to change (target engagement) | Research or commercial lipid tests only; fasting sample; 2 mg/day did not raise plasma levels in one trial (Fujino 2022); rosuvastatin lowers readings (Ng 2014) |
| ALT | 7–55 U/L (standard reference range) | Safety check: a rise stops or changes precursor use | Alanine aminotransferase, a liver enzyme; pair with AST; precursor-related rise reported (Smith 2025); avoid testing within 24 hours of hard exercise |
| AST | 8–48 U/L (standard reference range) | Safety check: a rise stops or changes precursor use | Aspartate aminotransferase, a liver and muscle enzyme; interpret with ALT and creatine kinase (a muscle enzyme released by muscle strain) after exercise |
| Triglycerides (shark liver oil or alkylglycerol users) | Below 150 mg/dL (standard reference range) | Marker expected to change with alkylglycerol precursors | Fasting 9–12 hours; fell versus placebo with shark liver oil (Paul 2021) |
| Cognitive test score (e.g., MoCA or Cognitrax) | No established target; track change from own baseline | Marker expected to change (memory outcome) | MoCA is the Montreal Cognitive Assessment; same test version and time of day each time; Cognitrax was used in the healthy-adult trials (Watanabe 2020; Fukuchi 2026) |
Qualitative markers:
- Everyday memory, such as recalling names and appointments
- Mental fatigue and concentration during long tasks
- Mood, irritability, and sense of vigor
- Sleep quality and morning alertness
- Digestive tolerance, especially with oil-based precursors
Emerging Research
- Sleep trial: 44 Japanese adults with morning sleepiness took plasmalogen capsules or placebo for 12 weeks; primary endpoint is sleepiness on rising (NCT06907537). Completed December 2025, no results posted. A positive result would add a sleep benefit; a null result would weaken the mood and sleep signals.
- Long-term safety trial: 24 healthy Japanese adults, 12 weeks, primary endpoint adverse events (NCT06715475). Registered completion April 2025 has passed; status not updated, no results posted. No excess adverse events would support the Low risk grades; a harm signal would add a risk.
- Precursor phase 1 trial: 40 adults with age-related cognitive decline taking ProdromeNeuro; primary endpoint change in the company’s blood test (NCT05041088). Completion date November 2023 passed, status unknown, no results. Positive data would replace the retracted precursor evidence; null data would weaken the precursor approach.
- Obesity mood trial: 83 obese adults, 1 mg/day scallop plasmalogen for 12 weeks, primary endpoint POMS 2 (NCT03295188). Completed 2018; no results posted or publication found. Publication would show whether the athlete mood finding replicates; continued silence raises concern about unpublished null results.
- RCDP natural history study: ongoing, recruiting about 75 patients, estimated completion December 2027, sponsored by PPI-1011 developer Med-Life Discoveries (NCT04031287). Positive baseline data would enable a controlled PPI-1011 efficacy trial; failure to define endpoints would delay any clinical proof that raising plasmalogens changes outcomes.
- Plasmalogen score as a modifiable marker: the score tracked mortality (Beyene 2024) and shifted sharply with shark liver oil (Beyene 2024); trials using it as an endpoint could strengthen or weaken the cardiometabolic case.
- Ether lipids and ferroptosis: cell work showing ether lipids drive ferroptosis (Zou 2020) could reveal either neuronal harm from oversupply or a lever against cancer, shifting the risk assessment.
Conclusion
Plasmalogens are membrane fats that the body makes itself and that are especially rich in the brain, heart, and immune cells. Supplements come in two forms: tiny daily amounts of purified scallop or sea squirt extracts, and much larger doses of oils that the body converts into plasmalogens.
For people pursuing a longer healthy life, the main attraction is brain health. Small company-run studies in healthy but forgetful adults reported better memory, and one study in young athletes reported less fatigue and irritability, yet the largest study, in people with early memory problems or mild Alzheimer’s disease, found no overall benefit. Links between high natural plasmalogen levels and lower heart disease, diabetes, and death rates describe the body’s own levels, not supplements. A small study of a related shark liver oil product improved blood fats.
The safety record over a few months is reassuring at the doses studied, with digestive upset no more common than with placebo. Very high doses of a synthetic version raised liver enzymes in a few participants, and seafood allergy is a plausible concern with marine extracts.
The evidence base is thin and short-term, and most of it was paid for by companies or a society funded by manufacturers. The only published study of the high-dose oils in people with memory problems was retracted. Taken together, plasmalogens remain an early-stage option whose memory benefit is uncertain and whose long-term safety is unknown.